EP0945465B1 - Anticorps monoclonaux antagonistes contre la molécule humaine CD40 - Google Patents

Anticorps monoclonaux antagonistes contre la molécule humaine CD40 Download PDF

Info

Publication number
EP0945465B1
EP0945465B1 EP99104709A EP99104709A EP0945465B1 EP 0945465 B1 EP0945465 B1 EP 0945465B1 EP 99104709 A EP99104709 A EP 99104709A EP 99104709 A EP99104709 A EP 99104709A EP 0945465 B1 EP0945465 B1 EP 0945465B1
Authority
EP
European Patent Office
Prior art keywords
cells
cell
human
antibodies
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
EP99104709A
Other languages
German (de)
English (en)
Other versions
EP0945465A1 (fr
Inventor
Mark De Boer
Leah B Conroy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27360277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0945465(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/910,222 external-priority patent/US5397703A/en
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Priority to EP06076491.7A priority Critical patent/EP1834671A3/fr
Publication of EP0945465A1 publication Critical patent/EP0945465A1/fr
Application granted granted Critical
Publication of EP0945465B1 publication Critical patent/EP0945465B1/fr
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • the present invention relates to antibodies directed against membrane-associated antigen molecules. More specifically, the present invention describes methods of using these membrane-associated antigens for the immunization of a host animal and for screening antibodies isolated from the host animal. Also, this invention relates to novel methods of treating diseases of the immune system. In particular, this invention relates to methods of preventing or treating antibody-mediated diseases such as IgE-mediated disease (allergies) and autoimmune diseases including sytematic lupus erythematosus (SLE), primary biliary cirrhosis (PBC), and idiopathic thrombocytopenic purpura (ITP).
  • IgE-mediated disease allergies
  • SLE sytematic lupus erythematosus
  • PBC primary biliary cirrhosis
  • ITP idiopathic thrombocytopenic purpura
  • Monoclonal antibodies have proven to be powerful tools in immunological research.
  • monoclonal antibodies can be produced using impure antigens as immunogens, provided that there is available a screening assay which distinguishes antibodies directed against the antigen of interest from antibodies directed against other antigens present in the immunogenic composition.
  • the antigen of interest is a cell surface molecule, it is desirable to use cells or membrane fractions containing the molecule of interest as immunogens in order to preserve the conformational constraints provided by a membrane environment.
  • Immunizing mice with whole cells usually yields a strong immune response which generates antibodies to a large number of different molecules. This broad immune response precludes the use of the immunogen cells in subsequent screening for specific antibody production by hybridoma clones derived from the mouse spleen or lymphocyte cells.
  • the frequency of mouse B cells specific for the antigen will be relatively low. This low frequency necessitates the screening of large numbers of hybridoma clones to identify a clone which produces antibodies directed against the antigen of interest.
  • Syngeneic murine fibroblasts expressing human cell surface antigens have been used to immunize mice for specific antibody production (DiSanto et al. , 1991).
  • the background antigen proteins present on the fibroblasts should not be immunogenic, so that the immune response should be focused on the xenogeneic recombinant protein.
  • this approach requires the construction of specific recombinant cells for each species or strain in which antibody production is desired.
  • B cells play an important role during the normal in vivo immune response.
  • a foreign antigen will bind to surface immunoglobulins on specific B cells, triggering a chain of events including endocytosis, processing, presentation of processed peptides on MHC-class II molecules, and up-regulation of the B7 antigen on the B-cell surface.
  • a specific T cell then binds to the B cell via T-cell receptor (TCR) recognition of processed antigen presented on the MHC-class II molecule. Stimulation through the TCR begins to activate the T cell and initiates T-cell cytokine production. Interaction between the CD28 antigen on T cells and the B7 antigen on B cells can provide a second signal further activating the T cell, resulting in high level cytokine secretion.
  • TCR T-cell receptor
  • the CD40 ligand which is not expressed on resting human T cells, is up-regulated on the T-cell surface when the above-mentioned signals are received.
  • the B cell is then stimulated by the CD40 ligand through the CD40 antigen on the B-cell surface, and also by soluble cytokines, causing the B cell to mature into a plasma cell secreting high levels of soluble immunoglobulin.
  • the CD40 antigen is a glycoprotein expressed on the cell surface of B cells. During B-cell diferentiation the molecule is first expressed on pre-B cells and then disappears from the cell surface when the B cell becomes a plasma cell. Crosslinking of the CD40 molecules with anti-CD40 antibodies mediates a variety of effects on B cells.
  • the CD40 antigen is known to be related to the human nerve growth factor (NGF) receptor and tumor necrosis factor-alpha (TNF- ⁇ ) receptor, suggesting that CD40 is a receptor for a ligand with important functions in B-cell activation.
  • a ligand for CD40 has been identified on the cell surface of activated T cells. Fenslow et al., J. Immunol. (1992) 149 :655; Lane et al., Eur. J. Immunol. (1992) 22 :2573; Noelle et al., Proc. Natl. Acad. Sci. (USA) (1992) 89 :6550. cDNA cloning of the CD40 ligand revealed a molecule with characteristics of a type-II transmembrane glycoprotein with homology to TNF- ⁇ . Armitage et al., Nature (1992) 357 :80 and Spriggs et al., J. Exp. Med. (1992) 176 :1543.
  • the extracellular domain of the CD40 ligand contains two arginine residues proximal to the transmembrane region, providing a potential proteolytic cleavage site that could give rise to a soluble form of the ligand.
  • Expression of recombinant CD40 ligand has demonstrated that this molecule can stimulate the proliferation of purified B cells and, in combination with IL-4, mediate the secretion of IgE. Armitage et al. and Spriggs et al., supra.
  • Anti-CD40 monoclonal antibodies can induce intercellular adhesion, proliferation and, in combination with certain cytokines, maturation to antibody secreting cells.
  • known anti-CD40 mAbs have been shown to mimic the effects of T helper cells in B-cell activation. When presented on adherent cells expressing Fc ⁇ RII, these antibodies induce B-cell proliferation. J. Banchereau et al., Science (1989) 251 :70.
  • known anti-CD40 mAbs can replace the T helper signal for secretion of IgM, IgG and IgE in the presence of IL-4. H. Gascan et al., J. Immunol. (1991) 147 :8. Furthermore, known anti-CD40 mAbs can prevent programmed cell death (apoptosis) of B cells isolated from lymph nodes.
  • the present invention provides a method for generating monoclonal antibody-producing cells, where the antibodies have binding specificity for a specific cell-surface molecule; this method overcomes the limitations of the above-described methods.
  • the invention also provides methods for the use of anti-CD40 antibodies that are (1) capable of inhibiting the B-cell response and (2) can be used to prevent or treat antibody-mediated disease.
  • the invention is based on the discovery of anti-CD40 antibodies that do not stimulate the growth and differentiation of human B cells. In contrast, these antibodies can inhibit human B-cell responses at relatively low concentrations. Accordingly, these antibodies can be used to prevent or treat diseases or conditions that are mediated by antibodies produced by the human B-cell response. These antibodies also recognize novel epitopes on the CD40 antigen useful in modulating the B-cell response.
  • this invention provides a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell.
  • the antibodies can be used in a method for preventing or treating an antibody-mediated disease in a patient, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell, in a pharmaceutically acceptable excipient.
  • the antibodies can be used in a method for preventing or treating an IgE-mediated disease such as an allergy in a patient, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell, in a pharmaceutically acceptable excipient.
  • the antibodies can be used in a method for preventing or treating an antibody-mediated autoimmune disease in a patient, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell, in a pharmaceutically acceptable excipient.
  • autoimmune diseases contemplated for treatment by this method include sytematic lupus erythematosus (SLE), primary biliary cirrhosis (PBC), and idiopathic thrombocytopenic purpura (ITP).
  • the anti-CD40 monoclonal antibody is made by the above described methods, and is either 5D12 (ATCC HB 11339) or 3C6 (ATCC HB 11340).
  • membrane-associated antigen As used herein, the term “membrane-associated antigen”, “cell surface molecule” and “cell surface antigen” all refer to a protein, polypeptide or peptide, where at least one antigenic portion of the protein, polypeptide or peptide is exposed on a surface of a biological membrane and which may have one or more of the following moieties covalently attached: one or more simple or complex sugar moieties (as in a glycoprotein), lipid moieties (as in a lipoprotein), a combination of lipid and sugar moieties, or other post-translational modifications.
  • Proteins are typically long chains of amino acid based polymers ("polypeptides"). Proteins may be composed of one, two or more polypeptide chains and may further contain some other type of substance in association with the polypeptide chain(s), such as carbohydrates. The size of proteins covers a rather wide range from (an arbitrary figure of) 5,000 to several hundred thousand g/mole. The 5,000 figure corresponds to the presence of roughly 40-45 amino acids. Proteins smaller than about 5,000 g/mole are typically referred to as polypeptides or simply peptides (Bohinski).
  • antibody refers to polyclonal antibodies, monoclonal antibodies, humanized antibodies, single-chain antibodies, and fragments thereof such as F ab , F (ab')2 , F v , and other fragments which retain the antigen binding function of the parent antibody.
  • the term "monoclonal antibody” refers to an antibody composition having a homogeneous antibody population.
  • the term is not limited regarding the species or source of the antibody, nor is it intended to be limited by the manner in which it is made.
  • the term encompasses whole immunoglobulins as well as fragments such as F ab , F (ab')2 , F v , and others which retain the antigen binding function of the antibody.
  • Monoclonal antibodies of any mammalian species can be used in this invention. In practice, however, the antibodies will typically be of rat or murine origin because of the availability of rat or murine cell lines for use in making the required hybrid cell lines or hybridomas to produce monoclonal antibodies.
  • humanized antibodies means that at least a portion of the framework regions of an immunoglobulin are derived from human immunoglobulin sequences.
  • single chain antibodies refer to antibodies prepared by determining the binding domains (both heavy and light chains) of a binding antibody, and supplying a linking moiety which permits preservation of the binding function. This forms, in essence, a radically abbreviated antibody, having only that part of the variable domain necessary for binding to the antigen. Determination and construction of single chain antibodies are described in U.S. Patent No. 4,946,778 to Ladner et al.
  • the term "molecule which binds to the B7 antigen" means a molecule which is capable of forming a complex with the B7 antigen in an environment wherein other substances in the same environment are not complexed to the B7 antigen.
  • the complex is formed in a manner that blocks the normal signal transduction pathway of B7 through the CD28 or CTLA4 antigen.
  • Molecules which bind to the B7 antigen include CD28, CTLA4, CTLA4Ig and anti-B7 antibodies.
  • CD40 antigen epitope refers to a molecule which is capable of immunoreactivity with the anti-CD40 monoclonal antibodies of this invention, excluding the CD40 antigen itself.
  • CD40 antigen epitopes may comprise proteins, protein fragments, peptides, carbohydrates, lipids, and other molecules, but for the purposes of the present invention are most commonly proteins, short oligopeptides, oligopeptide mimics (i.e., organic compounds which mimic the antibody binding properties of the CD40 antigen), or combinations thereof. Suitable oligopeptide mimics are described, inter alia, in PCT application US91/04282.
  • transfected insect cells of the present invention may also be used in screening assays.
  • the invention includes a method for producing polyclonal antibodies to a cell surface antigen.
  • the method involves the following steps: the immunization step, which includes (i) selecting and isolating a nucleic acid coding sequence which encodes the antigen of interest, (ii) inserting the coding sequence into a baculoviral expression vector so as to obtain efficient expression of the coding sequence, (iii) transfecting the expression vector into an insect cell line to obtain recombinant insect cells expressing the selected antigen, and (iv) immunizing a host animal with the insect cells expressing the membrane-associated antigen.
  • the serum of the host animal is screened against cells, other than the insect cells, expressing the antigen of interest.
  • membrane fractions containing the antigen of interest, or in some cases, purified recombinantly-produced antigens themselves can be used to screen the serum.
  • (a) pre-bleed serum (b) the serum of a host animal immunized with insect cells not expressing the antigen of interest, and (c) the serum of the host animal immunized with the recombinant insect cells are screened.
  • the presence of antibodies specifically directed against the antigen of interest is indicated by negative reactions with sera (a) and (b), and positive reactions with serum (c).
  • the invention includes a method for the generation of hybridomas which produce monoclonal antibodies to a cell surface protein.
  • the method involves the steps (i) to (iv) described above.
  • antibody-producing cells are isolated from the animal.
  • such antibody-producing cells are used to generate hybridoma cells, which are cloned and used for the production of monoclonal antibodies.
  • Supernatants from such hybridoma cells are screened for specific antibody production, for example, using a cell-based screening assay described below.
  • the nucleic acid coding sequence for a selected membrane-associated antigen can be isolated based on known amino acid and/or DNA coding sequences for the protein component of the antigen.
  • the coding sequence can be isolated from biological sources by standard procedures (Ausubel, et al.; Maniatis, et al.; Sambrook, et al.) (e.g., hybridization, differential hybridization, cloning and plaque screening, etc.).
  • synthetic oligonucleotide sequences encoding the antigen of interest can be prepared using commercially available automated oligonucleotide synthesizers or may be purchased, for example, from Synthetic Genetics (San Diego, CA).
  • the oligonucleotide coding sequence can be synthesized through a series of cloning steps involving a tandem array of multiple oligonucleotide fragments corresponding to the coding sequence (Crea; Yoshio et al .; Eaton et al .). Oligonucleotide coding sequences can be amplified and isolated by standard recombinant procedures (Maniatis et al. ; Ausubel et al. ) or by polymerase chain reaction (Mullis; Mullis, et al.) . When the sequence of the membrane associated antigen is known or partially known a specific antigen coding sequence may be isolated.
  • the antigen coding sequence is isolated from a cDNA library, generated by the insertion of DNA fragments from a selected source into a vector.
  • the cDNA library containing DNA fragments from a membrane antigen-containing source can be constructed using random fragments cDNA molecules generated from target RNA molecules.
  • Such a cDNA library is generally constructed using a bacterial system (such as lambda gt10 (Promega, Madison WI)), but can also be constructed in a yeast or eukaryotic expression system using conventional techniques (Ausubel).
  • the library is screened (usually by hybridization; Ausubel, et al .; Maniatis, et al .) for the presence of the membrane-associated antigen DNA sequence, typically using as a probe an oligonucleotide having a known or consensus sequence hybridizable with the antigen coding region.
  • the probe can carrying a number of detection moieties including radioisotopes, biotin and digoxigenin.
  • screening for clones carrying the coding region of interest can be carried out using, for example, immunoscreening (using "PROTOCLONE" lambda gt11 system, Promega; Young, et al.; Huynh, et al.).
  • Coding regions are isolated from recombinant isolates giving positive signals (either by hybridization or immunological screening). Typically, DNA fragments containing the coding regions are isolated by restriction digestion followed by size fractionation and fragment purification. Such nucleic acid coding regions may then be processed for insertion into a baculoviral transfer vector, such as the vector pAcC8 ( Figure 1A), as described in part B, below.
  • baculoviral transfer vector such as the vector pAcC8 ( Figure 1A), as described in part B, below.
  • Alternative baculovirus vectors are available including the vectors pVL1393 (Luckow et al. ) and pAC3T3 (Summers et al. ).
  • coding sequences can also be isolated using polymerase chain reaction (PCR) amplification (Mullis; Mullis, et al .).
  • Primers useful for the PCR can be derived from any known nucleic acid sequence. If the exact sequence is not known degenerative primers can be used (Mullis; Mullis, et al .).
  • these primers are two nucleic acid sequences consisting of 8 or more colinear nucleotides, where the two sequences are separate by some defined distance, in order to generate a target sequence (Example 1), and are complementary to opposite strands.
  • a typical PCR cycle involved the following steps: melting at elevated temperature, followed by annealing, and extension. The reactions are repeated for 25-30 cycles.
  • the PCR products can be digested with restriction enzymes and electrophoretically resolved using a preparative 1.5% agarose gel. Clone-specific, amplified fragments are typically identified by electrophoretic gel size fractionation.
  • the clone-specific DNA fragments are then recovered from the gel, for example, using the "GENE CLEAN" system (BIO 101, La Jolla CA). If necessary the DNA can be extracted with phenol and/or phenol:chloroform (1:1). Isolated DNA is ethanol precipitated. Following precipitation, the DNA is used for insertion into baculovirus expression vectors.
  • RNA is isolated from a population of Epstein-Barr virus (EBV)-transformed human spleen cells, using standard procedures (Chirgwin, et al. ). Total RNA is converted to cDNA using random hexamer priming, according to established methods, and as detailed in Example 1.
  • the DNA molecule encoding the membrane-associated antigen molecules of interest is generated by PCR amplification, using forward and reverse primers having restriction sites for cloning at their 5' termini.
  • Such cDNA primers, used in the preparation of coding regions for human CD40 are depicted in Figure 2. These primers were constructed on the basis of the published complete DNA coding sequences for CD40 Stamenkovic et al. , 1989).
  • the cDNA is mixed with a forward primer and a reverse primer, in the presence of a thermostable polymerase, such as polymerase obtained from Thermus aquaticus, a mixture of equimolar deoxynucleotides, and a buffer system (Example 1) .
  • a thermostable polymerase such as polymerase obtained from Thermus aquaticus
  • a mixture of equimolar deoxynucleotides such as polymerase obtained from Thermus aquaticus
  • a buffer system Example 1
  • the mixture is subjected to amplification in a thermocycler, and PCR products obtained are subcloned in the polylinker of a baculovirus transfer vector.
  • pAcC8 is diagrammatically represented in Figure 1A.
  • any of a number of such baculoviral transfer vectors containing unique restriction endonuclease sites downstream of the polyhedrin promoter can be utilized in the practice of the present invention: for Autographica californica nuclear polyhedrosis virus (AcNPV) (Wu, et al .; Matsuura, et al .; Takehara, et al .) or Bombyx mori nuclear polyhedrosis virus (pBmNPV) polyhedrin mRNA (Nyunoya, et al.; Sekine, et al .).
  • AcNPV Autographica californica nuclear polyhedrosis virus
  • pBmNPV Bombyx mori nuclear polyhedrosis virus
  • DNA inserts are typically checked for PCR-induced mutations by sequencing analysis.
  • Insertion of the membrane-associated antigen coding region into a baculovirus-vector is performed according to established procedures (Ausubel, et al.; Maniatis, et al.; Sambrook, et al .).
  • Full length cDNAs encoding human B7 and human CD40 were generated by PCR using primers with restriction sites for cloning.
  • the template for PCR amplification was cDNA generated from EBV-transformed human spleen B cell RNA.
  • an isolated DNA coding region is ligated into the baculoviral transfer vector or plasmid, such as a pAcC8 plasmid, so that the membrane-associated coding region is down-stream of the polyhedron promoter.
  • the polyhedron gene ATG has been mutated to ATT ( Figure 1A) to prevent translational initiation in recombinant clones that do not contain a coding sequence with a functional ATG.
  • the resulting plasmid DNA is co-transfected with wild type baculovirus (AcNPV) into insect cells from Spodoptera frugiperda (Sf9 cells) to create recombinant virus particles, via in vivo recombination between the wild type virus and the recombinant vector, carrying the membrane-associated antigen gene.
  • AcNPV wild type baculovirus
  • Sf9 cells Spodoptera frugiperda
  • Examples 1-2 describe the isolation of recombinant baculovirus vectors containing heterologous segments of DNA: pAcCD40 (encoding a full-length CD40 molecule), pAcCD40-ED/Glu (encoding the extracellular domain of CD40), pAcB7 (encoding a full-length B7 molecule) and pCcB7-ED/Glu (encoding the cellular domain of the B7 molecule).
  • the recombinant viruses described above were then used to co-infect insect cells (Example 2). These cells then expressed the antigens encoded by the heterologous DNA inserts.
  • Sf9 cells (Spodoptera frugiperda; Summers, et al .), at a density of 10 6 cells/ml, were infected with recombinant virus. Recombinant baculovirus-infected Sf9 cells were identified and clonally purified (Summers et al. ).
  • Cells expressing cell surface antigen were harvested after 48 hours and used for the immunization of host animals. For production of secreted recombinant proteins, the cells were harvested after 72 hours of culture.
  • Sf9 cells expressing selected membrane-associated antigens can be used to screen sera and hybridoma supernatants for the presence of antibodies reactive against the selected antigen.
  • Appropriate host animals for the production of polyclonal antibodies include, for example, rabbits, goats, sheep, guinea pigs, chimpanzees and dogs.
  • immunization adjuvants are generally not required.
  • Appropriate host animals for use in the production of monoclonal antibodies commonly include rats, hamsters and mice. However, in cases where it is desirable to produce antibodies that are immunologically closer to humans, sources of such antibodies may include higher primates such as chimpanzees. Fusion with a heteromyeloma fusion partner can be used for the generation of monoclonal antibodies (Carroll; Perkins, 1991). Such fusions can be achieved by a number of methods known in the art (Harlow, et al.) including exposure of mixed cells to polyethylene glycol and exposure of cells to strong electric field (electrofusion). Hybridomas are selected by growth in selective medium, then are tested for antigen specificity as described below.
  • mice were immunized (Example 5) with the Sf9 cells expressing these molecules on the cell surface.
  • the mice were bled and the sera were analyzed for the presence of specific antibodies using fluorescent cell staining of EBV-transformed B cells (Example 3).
  • Figure 5 shows the results of the cell staining which indicate that mice immunized with Sf9 cells expressing CD40 or B7 had a serum titre against EBV-transformed B cell line ARC (American Type Culture Collection (A.T.C.C.), 12301 Parklawn Dr., Rockville MD 20852), which is positive for both CD40 and B7.
  • ARC American Type Culture Collection (A.T.C.C.), 12301 Parklawn Dr., Rockville MD 20852
  • mice which were immunized with control Sf9 cells showed no reactivity with the ARC cells.
  • the results indicate that host animals can be immunized with Sf9 cells expressing a membrane-associated antigen of choice and the immunization results in an immune response including antibodies against the recombinant antigen.
  • the immunization does not result in antibodies cross-reactive with human proteins other than the recombinant human protein cloned in the Sf9 insect cells.
  • One mouse was given a final booster injection with CD40 expressing Sf9 cells and one with B7 expressing Sf9 cells. Three days after the booster injection, the spleens were removed and the splenocytes were fused with SP2/0 murine myeloma cells.
  • Antibody-producing lymphocytes for monoclonal antibody production are preferably B-lymphocytes, such as may be isolated from the bone marrow, spleen or lymph nodes of an immune host animal (Harlow, et al.).
  • B-lymphocytes can be isolated from the peripheral circulation.
  • blood samples are centrifuged, and are subjected to gradient separation techniques to produce a crude peripheral blood lymphocyte (PBL) mixture.
  • Monocytes and T-lymphocytes are selectively depleted from this cell mixture according to established procedures (Mishell).
  • Such remaining cells may be subjected to a selection procedure, such as a "panning" procedure, in which those cells having affinity for the antigen are concentrated by selective capture by an affinity matrix containing the antigen.
  • a matrix might comprise a cell which expresses the membrane-associated antigen.
  • B-lymphocytes When B-lymphocytes are isolated from the circulation as described above, transformation with a transforming virus, such as Epstein-Barr virus, may be advantageous.
  • Transformed cells (lymphoblastoids) are dispensed in subculture wells and maintained in culture for several weeks, prior to testing for specific antibody production. Cultures exhibiting such specific antibody production are expanded and fused with species-appropriate myeloma partner cells using one or more standard fusion protocols, including polyethylene glycol, as described above, or electrofusion.
  • mice were fused with SP2/0 murine myeloma cells polyethylene glycol as previously described by de Boer et al . (1988).
  • the hybridoma clones were processed as described in Example 6.
  • Table 1 (Example 6) gives a summary of the fusion data.
  • Table 1 (Example 6) gives a summary of the fusion data.
  • the CD40 fusion only half of the cells were seeded in 480 wells. This resulted in 351 wells with hybridoma growth.
  • the B7 fusion the cells were distributed in 960 wells and this fusion yielded 312 wells with hybridoma growth.
  • supernatants of 12 wells were pooled and the pools were tested for the presence of antibodies reactive with ARC cells.
  • FACS analysis revealed that 4 pools from the CD40 fusion and 1 pool from the B7 fusion were reactive with ARC cells. When individual supernatants from the positive pools were retested, 4 wells reactive with CD40 and 1 well reactive with B7 were identified.
  • the cells from these positive wells were cloned by limiting dilution, and, after 3 rounds of cell growth, 4 stable anti-(CD40) hybridoma clones (CD40-3A8, CD40-3C6, CD40-5D12 and CD40-5 and 1 stable anti-(B7) hybridoma clone (B7-24) were established. These results indicate the ability to achieve stable hybridoma clones secreting monoclonal antibodies directed against a chosen membrane-associated antigen.
  • a number of methods for screening hybridoma fusions are available (Harlow, et al .), including: antibody capture, (i) using labeled antigen, e.g., radioactively labelled partially purified or purified antigen, (ii) whole or permeabilized cells, e.g., Sf9 cells expressing the recombinant antigen; and antigen capture, (i) antibody/antigen in solution, (ii) antibody/antigen solid phase.
  • labeled antigen e.g., radioactively labelled partially purified or purified antigen
  • whole or permeabilized cells e.g., Sf9 cells expressing the recombinant antigen
  • EBV-transformed cells were used for the screening of the primary hybridoma supernatants and for screening of the subsequent products of the limiting dilution cloning.
  • Several lines of evidence presented below suggest that 4 anti-(CD40) and 1 anti-(B7) monoclonal antibodies have been generated.
  • the anti-(CD40) and anti-(B7) monoclonal antibodies were tested for their ability to bind to tonsillar B cells (Example 8).
  • Table 2 shows that 89-95 percent of freshly isolated tonsillar B cells stained positive with the four anti-(CD40) monoclonal antibodies. About the same percentage of cells was positive with anti-(CD40) monoclonal antibody G28.5 (Clark, et al .).
  • Table 3 shows that 12-17 percent of freshly isolated tonsillar B cells stained positive with anti-(B7) monoclonal antibody B7-24.
  • the percentage of cells positive for B7-24 increased up to about 25 percent.
  • tonsillar B cells were stimulated with anti-(IgM) antibodies and IL-2, not only did the number of B cells positive for B7-24 increase, but there was also a significant increase in the amount of fluorescent staining per cell, indicating that the expression of B7 was increased after stimulation.
  • the above data indicate that the method of the present invention provides a way to isolate monoclonal antibodies which are specifically reactive with membrane-associated antigens.
  • the monoclonal antibodies obtained by the method of the present invention can be typed as previously described (Harlow, et al. ).
  • the method of the present invention involves the expression of membrane-associated antigens in insect cells and the use of these insect cells to immunize host animals. Since the introduction of PCR technology (Saiki et al ., 1985; Saiki et al ., 1988; Mullis; Mullis, et al .), it has become relatively straight-forward to clone cDNAs for proteins whose coding nucleic acid coding sequence has been published. One can use PCR primers spanning the complete coding region only, and incorporate restriction sites in these primers to facilitate cloning into expression vectors.
  • Antibodies obtained by the method of the present invention directed against membrane-associated antigens, are advantageous for use as diagnostic agents for the detection of the membrane-associated antigen.
  • antibodies directed against cell-surface marker proteins or viral proteins protruding from the cell surface are advantageous for use as diagnostic agents for the detection of the membrane-associated antigen.
  • antibodies directed against cell-surface marker proteins or viral proteins protruding from the cell surface are advantageous for use as diagnostic agents for the detection of the membrane-associated antigen.
  • One diagnostic configuration involves use of anti-viral antibodies capable of detecting viral specific antigens.
  • the antigens may be detected, for example, using an antigen capture assay where viral antigens present in candidate serum samples are reacted with an antigen-specific monoclonal or polyclonal antibody. The antibody is bound to a solid substrate and the antigen is then detected by a second, different labelled antibody directed against the anti-viral antibody.
  • the anti-viral antibodies obtained by the method of the invention can be used as a means of enhancing an anti-viral immune response since antibody-virus complexes are typically recognized by macrophages and other effector cells.
  • the antibodies can be administered in amounts similar to those used for other therapeutic administrations of antibody.
  • pooled gamma globulin is administered at 0.02-0.1 ml/lb body weight during the early incubation of viral diseases such as rabies, measles and hepatitis B to interfere with viral entry into cells.
  • antibodies reactive with a membrane-associated viral antigen can be passively administered alone, in a "cocktail" with other anti-viral antibodies, or in conjunction with another anti-viral agent to enhance the immune response and/or the effectiveness of an antiviral drug.
  • This invention contemplates the use of monoclonal antibodies such as those made by the above-described method.
  • the antibodies of the current invention bind to a human CD40 antigen on the surface of a human B cell and do not stimulate the growth of differentiation of the B cell.
  • These monoclonal antibodies may be humanized antibodies, single-chain antibodies, and fragments thereof.
  • Monoclonal antibodies 5D12, 3A8 and 3C6 are prepared as in section II of the detailed description and Examples 1-7 herein.
  • Other monoclonal antibodies of the invention may be prepared similarly, or as follows. First, polyclonal antibodies are raised against the CD40 antigen. Second, monoclonal antibodies specific for CD40 are selected.
  • Polyclonal sera may be prepared by conventional methods.
  • a solution containing the CD40 or B7 antigen is first used to immunize a suitable animal, preferably a mouse, rat, rabbit or goat. Rabbits and goats are preferred for the preparation of polyclonal sera due to the volume of serum obtainable, and the availability of labeled anti-rabbit and anti-goat antibodies.
  • Immunization is generally performed by mixing or emulsifying the antigen-containing solution in saline, preferably in an adjuvant such as Freund's complete adjuvant, and injecting the mixture or emulsion parenterally (generally subcutaneously or intramuscularly). A dose of 50-200 ⁇ g/injection is typically sufficient.
  • Immunization is generally boosted 2-6 weeks later with one or more injections of the protein in saline, preferably using Freund's incomplete adjuvant.
  • Polyclonal antisera are obtained by bleeding the immunized animal into a glass or plastic container, incubating the blood at 25oC for one hour, followed by incubating at 4oC for 2-18 hours.
  • the serum is recovered by centrifugation (e.g., 1,000 x g for 10 minutes). About 20-50 ml per bleed may be obtained from rabbits.
  • Monoclonal antibodies are prepared using the method of Kohler and Milstein, Nature (1975) 256:495-96, or a modification thereof.
  • a mouse or rat is immunized as described above.
  • the spleen and optionally several large lymph nodes
  • the spleen cells may be screened (after removal of nonspecifically adherent cells) by applying a cell suspension to a plate or well coated with the protein antigen.
  • B-cells expressing membrane-bound immunoglobulin specific for the antigen bind to the plate, and are not rinsed away with the rest of the suspension.
  • Resulting B-cells, or all dissociated spleen cells are then induced to fuse with myeloma cells to form hybridomas, and are cultured in a selective medium (e.g ., hypoxanthine, aminopterin, thymidine medium, "HAT").
  • a selective medium e.g ., hypoxanthine, aminopterin, thymidine medium, "HAT”
  • the resulting hybridomas are plated by limiting dilution, and are assayed for the production of antibodies which bind specifically to the desired immunizing cell-surface antigen (and which do not bind to unrelated antigens).
  • the selected mAb-secreting hybridomas are then cultured either in vitro (e.g ., in tissue culture bottles or hollow fiber reactors), or in vivo (as ascites in mice).
  • the antibodies may be labeled using conventional techniques. Suitable labels include fluorophores, chromophores, radioactive atoms (particularly 32 P and 125 I), electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes are typically detected by their activity. For example, horseradish peroxidase is usually detected by its ability to convert 3,3',5,5'-tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a spectrophotometer. "Specific binding partner” refers to a protein capable of binding a ligand molecule with high specificity, as for example in the case of an antigen and a monoclonal antibody specific therefor.
  • 125 I may serve as a radioactive label or as an electron-dense reagent.
  • HRP may serve as enzyme or as antigen for a mAb.
  • mAbs and avidin also require labels in the practice of this invention: thus, one might label a mAb with biotin, and detect its presence with avidin labeled with 125 I, or with an anti-biotin mAb labeled with HRP.
  • Other permutations and possibilities will be readily apparent to those of ordinary skill in the art, and are considered as equivalents within the scope of the instant invention.
  • the CD40 antigen epitopes of this invention are molecules that are immunoreactive with anti-CD40 monoclonal antibodies whose binding to a human CD40 antigen located on the surface of a human B cell prevents the growth or differentiation of the B cell. That is, such epitopes compete with the binding of said antibodies to the CD40 antigen.
  • Systematic techniques for identifying these epiotpes are known in the art, as described by H.M. Geysen in U.S. Patent No. 4,708, 871.
  • these epitopes are short amino acid sequences. These sequences may be embedded in the sequence of longer peptides or proteins, as long as they are accessible.
  • the epitopes of the invention may be prepared by standard peptide synthesis techniques, such as solid-phase synthesis.
  • the sequences of the invention may be incorporated into larger peptides or proteins by recombinant methods. This is most easily accomplished by preparing a DNA cassette which encodes the sequence of interest, and ligating the cassette into DNA encoding the protein to be modified at the appropriate site.
  • the sequence DNA may be synthesized by standard synthetic techniques, or may be excised from the phage pIII gene using the appropriate restriction enzymes.
  • Epitopes identified herein may be prepared by simple solid-phase techniques. The minimum binding sequence may be determined systematically for each epitope by standard methods, for example, employing the method described by H.M. Geysen, U.S. Pat. No. 4,708,871. Briefly, one may synthesize a set of overlapping oligopeptides derived from the CD40 antigen bound to a solid phase array of pins, with a unique oligopeptide on each pin. The pins are arranged to match the format of a 96-well microtiter plate, permitting one to assay all pins simultaneously, e.g ., for binding to an anti-CD40 monoclonal antibody. Using this method, one may readily determine the binding affinity for every possible subset of consecutive amino acids.
  • Analogs of the invention are also prepared by standard solid-phase methods, and those methods described in PCT application US91/04282.
  • the antibodies and compositions of this invention are administered at a concentration that is therapeutically effective to prevent or treat antibody-mediated diseases such as allergies, SLE, PBC and ITP.
  • the antibodies or compositions may be formulated using a variety of acceptable excipients known in the art.
  • the antibodies or compositions are administered by injection, either intravenously or intraperitoneally. Methods to accomplish this administration are known to those of ordinary skill in the art. It may also be possible to obtain compositions which may be topically or orally administered, or which may be capable of transmission across mucous membranes.
  • formulants may be added to the antibodies.
  • a liquid formulation is preferred.
  • these formulants may include oils, polymers, vitamins, carbohydrates, amino acids, salts, buffers, albumin, surfactants, or bulking agents.
  • carbohydrates include sugar or sugar alcohols such as mono, di, or polysaccharides, or water soluble glucans.
  • the saccharides or glucans can include fructose, dextrose, lactose, glucose, mannose, sorbose, xylose, maltose, sucrose, dextran, pullulan, dextrin, alpha and beta cyclodextrin, soluble starch, hydroxethyl starch and carboxymethylcellulose, or mixtures thereof.
  • Sucrose is most preferred.
  • "Sugar alcohol” is defined as a C 4 to C 8 hydrocarbon having an -OH group and includes galactitol, inositol, mannitol, xylitol, sorbitol, glycerol, and arabitol. Mannitol is most preferred.
  • sugars or sugar alcohols mentioned above may be used individually or in combination. There is no fixed limit to amount used as long as the sugar or sugar alcohol is soluble in the aqueous preparation.
  • the sugar or sugar alcohol concentration is between 1.0 w/v% and 7.0 w/v%, more preferable between 2.0 and 6.0 w/v%.
  • amino acids include levorotary (L) forms of carnitine, arginine, and betaine; however, other amino acids may be added.
  • Preferred polymers include polyvinylpyrrolidone (PVP) with an average molecular weight between 2,000 and 3,000, or polyethylene glycol (PEG) with an average molecular weight between 3,000 and 5,000.
  • a buffer in the composition it is also preferred to use a buffer in the composition to minimize pH changes in the solution before lyophilization or after reconstitution.
  • Most any physiological buffer may be used, but citrate, phosphate, succinate, and glutamate buffers or mixtures thereof are preferred. Most preferred is a citrate buffer.
  • the concentration is from 0.01 to 0.3 molar.
  • Surfactants that can be added to the formulation are shown in EP Nos. 270,799 and 268,110.
  • antibodies can be chemically modified by covalent conjugation to a polymer to increase their circulating half-life, for example.
  • Preferred polymers, and methods to attach them to peptides are shown in U.S. Patent Nos. 4, 766, 106; 4,179,337; 4,495,285; and 4,609,546.
  • Preferred polymers are polyoxyethylated polyols and polyethylene glycol (PEG).
  • PEG is soluble in water at room temperature and has the general formula: R(O-CH 2 -CH 2 ) n O-R where R can be hydrogen, or a protective group such as an alkyl or alkanol group.
  • the protective group has between 1 and 8 carbons, more preferably it is methyl.
  • n is a positive integer, preferably between 1 and 1,000, more preferably between 2 and 500.
  • the PEG has a preferred average molecular weight between 1000 and 40,000, more preferably between 2000 and 20,000, most preferably between 3,000 and 12,000.
  • PEG has at least one hydroxy group, more preferably it is a terminal hydroxy group. It is this hydroxy group which is preferably activated to react with a free amino group on the inhibitor.
  • the type and amount of the reactive groups may be varied to achieve a covalently conjugated PEG/antibody of the present invention.
  • Water soluble polyoxyethylated polyols are also useful in the present invention. They include polyoxyethylated sorbitol, polyoxyethylated glucose, polyoxyethylated glycerol (POG), etc. POG is preferred. One reason is because the glycerol backbone of polyoxyethylated glycerol is the same backbone occurring naturally in, for example, animals and humans in mono-, di-, triglycerides. Therefore, this branching would not necessarily be seen as a foreign agent in the body. The POG has a preferred molecular weight in the same range as PEG. The structure for POG is shown in Knauf et al., 1988, J . Bio. Chem.
  • the liquid pharmaceutical composition is preferably lyophilized to prevent degradation and to preserve sterility.
  • Methods for lyophilizing liquid compositions are known to those of ordinary skill in the art.
  • the composition may be reconstituted with a sterile diluent (Ringer's solution, distilled water, or sterile saline, for example) which may include additional ingredients.
  • a sterile diluent Finger's solution, distilled water, or sterile saline, for example
  • the composition is preferably administered to subjects using those methods that are known to those skilled in the art.
  • the anti-CD40 antibodies and compositions of this invention are used to treat human patients to prevent or treat antibody-mediated diseases such as allergies, SLE, PBC and ITP.
  • the preferred route of administration for these antibodies is parenteral.
  • the compositions of this invention will be formulated in a unit dosage injectable form such as a solution, suspension or emulsion, in association with a pharmaceutically acceptable parenteral vehicle.
  • a pharmaceutically acceptable parenteral vehicle are inherently nontoxic and nontherapeutic. Examples of such vehicles are saline, Ringer's solution, dextrose solution, and Hanks' solution.
  • Nonaqueous vehicles such as fixed oils and ethyl oleate may also be used.
  • a preferred vehicle is 5% dextrose in saline.
  • the vehicle may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, including buffers and preservatives.
  • compositions are administered so that antibodies are given at a dose between 1 ⁇ g/kg and 20 mg/kg, more preferably between 20 ⁇ g/kg and 10 mg/kg, most preferably between 1 and 7 mg/kg.
  • it is given as a bolus dose, to increase circulating levels by 10-20 fold and for 4-6 hours after the bolus dose. Continuous infusion may also be used after the bolus dose.
  • the antibodies may be infused at a dose between 5 and 20 ⁇ g/kg/minute, more preferably between 7 and 15 ⁇ g/kg/minute.
  • Iscove's modification of Dulbecco's Eagle medium (IMDM) and foetal bovine serum were obtained from JR Biosciences (Lenexa, KS); penicillin and streptomycin were obtained from Irvine (Santa Ana, CA); and polyethylene glycol (mol. wt. 1500) was obtained from Boehringer Mannheim (Indianapolis, IN).
  • SP2/0 murine myeloma cells, hybridoma cells, purified T cells, EBV-transformed B cells and cell lines were cultured in IMDM supplemented with streptomycin (200 ⁇ g/ml), penicillin (200 U/ml) and 10% heat inactivated foetal bovine serum (complete IMDM).
  • streptomycin 200 ⁇ g/ml
  • penicillin 200 U/ml
  • 10% heat inactivated foetal bovine serum complete IMDM.
  • the Sf9 insect cells were cultured in shaker flasks agitated (125-150 rpm) in medium described by Maiorella et al . (1989) supplemented with 0.5% foetal bovine serum.
  • 3T6-Fc ⁇ RII cells were cultured in medium consisting of 50% Dulbecco's modified Eagle's medium and 50% HAM-F10 medium, supplemented with aminopterin (0.2 ⁇ g./ml), thymidine (5 ⁇ g/ml), xanthine (10 ⁇ g/ml), hypoxanthine (15 ⁇ g/ml), mycophenolic acid (20 ⁇ g/ml) deoxycytidine (2.3 ⁇ g/ml), and 10% heat-inactivated fetal bovine serum (complete DME/HAM-F10) .
  • 3T6-Fc ⁇ RII/B7 cells were cultured in complete DME/HAM-F10 medium containing 400 ⁇ g/ml G418 (Gibco).
  • Peripheral blood mononuclear cells were isolated from heparinized blood (obtained from healthy volunteers) by Ficoll-Hypaque density centrifugation. T cells were enriched by depleting monocytes and B cells using Lymphokwik (Lambda, California) (1 X).
  • Lymphokwik Lymphokwik (Lambda, California) (1 X).
  • 3T6-Fc ⁇ RII the mouse fibroblast cell line expressing CD32, the human Fc ⁇ RII high responder allele, as described by Warmerdam, P.A.M. et al., J. Exp. Med. (1990) 172 :19, was kindly provided by Dr. J. van de Winkel (University Hospital, Utrecht, The Netherlands).
  • the mutant mouse thymoma EL-4 subclone EL4B5 was a gift of Dr. R.H. Zubler, Hôpital Cantonal Universitaire, Geneva.
  • Mouse 3T6 transfectant cells expressing hybrid molecules of the HR (high responder) allelic form of human Fc ⁇ RIIa were a gift of Dr. P.A.M.
  • B lymphocytes were isolated from tonsils obtained from children undergoing tonsillectomies, essentially as described in De Groot et al., Lymphokine Research (1990) 9 :321. Briefly, the tissue was dispersed with scalpel blades, phagocytic and NK cells were depleted by treatment with 5 mM L-leucine methyl ester and T cells were removed by one cycle of rosetting with sheep erythrocytes (SRBC) treated with 2-aminoethyl isothiouronium bromide.
  • SRBC sheep erythrocytes
  • the purity of the resulting B lymphocyte preparations was checked by indirect immunofluorescent labelling with anti-(CD20) mAb B1 (Coulter Clone, Hialeah, FA) or anti-(CD3) mAb OKT3 (Ortho, Raritan, NJ) and a FITC-conjugated F(ab') 2 fragment of rabbit anti-(mouse Ig) (Zymed, San Francisco, CA), and FACS analysis.
  • the B cell preparations contained (mean ⁇ SD of 6 isolations): 95 ⁇ 4% CD20-positive cells and 2 ⁇ 1% CD3-positive cells.
  • Antibodies Anti-(human B7) monoclonal antibody BB-1 (Yokochi et al., 1982) was obtained from Dr. E.A. Clark (University of Washington, Seattle, WA) and was used as purified antibody.
  • Anti-(human CD26) monoclonal antibody Ta-1 and anti-(CD20) monoclonal antibody B1 were obtained from Coulter (Hialeah, FL).
  • Anti-(CD3) monoclonal antibody OKT3 was obtained from Ortho (Raritan, NJ), and the anti-(LeuM3) monoclonal antibody was obtained from Becton-Dickinson (San Jose, CA).
  • Anti-(IgM) antibodies coupled to beads were obtained from Bio-Rad (Richmond, CA).
  • Anti-B7 Mab B7-24 (IgG2a, x), and anti-CD40 mAbs 5D12, 3C6 and 3A8 were obtained as described in Section II above, and used as purified antibodies.
  • Anti-CD3 Mab CLB-T3/4.1 (IgG1, x) was used as diluted tissue culture supernatant and was kindly supplied by Dr. L. Aarden (Central Laboratory of the Red Cross Blood Transfusion Service, Amsterdam, The Netherlands).
  • Anti-CD3 Mab UCHT1 (IgG, x) was used as purified antibody and as a gift of Dr. P. Beverley (Imperial Research Cancer Fund, London, UK).
  • Anti-CD72 Mab WL225 (IgG2a, x) was used as purified antibody and was a gift of Dr. K. Thielemans (Vrije Universiteit Brussel, Belgium). The anti-ICAM-1 Mab 84H10 was used as diluted ascites fluid.
  • Anti-CD40 mAb S2C6 was a gift of Dr. S. Paulie (University of Sweden). Paulie et al., J. Immunol. (1989) 142 :590.
  • Anti-CD40 mAb G28.5 was donated by Dr. J.A. Ledbetter (Oncogen Corporation, Seattle, WA, USA). Clark et al., PNAS (USA) (1986) 83 :4494.
  • Control antibodies were: anti-( ⁇ -glucocerebrosidase) mAb 8E4 (IgG1), Barneveld et al., Eur. J. Biochem. (1983) 134 :585, and myeloma immunoglobulins MOPC-21 (IgG1) and MOPC-141 (IgG2b) (Sigma, St. Louis, MO). All mAb were used as purified antibody preparations.
  • hCD40.H ⁇ fusion protein was a gift of Dr. P. Lane (Basel Institute for Immunology, Basel, Switzerland) and was used as a 5x concentrated supernatant of transfected J558L cells. Lane et al., Eur. J. Immunol. (1992) 22 :2573.
  • the monoclonal antibodies of the present invention can be labeled, by standard methods, using a number of reporter moieties, including the following: fluorescent labels (fluorescein (FITC), R-phycoerythrin, rhodamine (TMRITC), rhodamine 600 (XRITC), "TEXAS RED,” and the like, commonly avidin linked); radioactive moieties ( 125 I and the like); light-emitting (luciferase and the like); enzymatic (horseradish peroxidase, alkaline phosphatase, glucose oxidase, ⁇ -galactosidase, and the like).
  • reporter antibodies antibodies which have binding specificity for the monoclonal antibodies of the present invention, e.g., goat anti-mouse IgG
  • E. coli DNA polymerase I (Klenow fragment) was obtained from Boehringer Mannheim Biochemicals (BMB) (Indianapolis, IN).
  • T4 DNA ligase and T4 DNA polymerase were obtained from New England Biolabs (Beverly, MA); Nitrocellulose filters are obtained from Schleicher and Schuell (Keene, NH).
  • Synthetic oligonucleotide linkers and primers were prepared using commercially available automated oligonucleotide synthesizers. Alternatively, custom designed synthetic oligonucleotides may be purchased, for example, from Synthetic Genetics (San Diego, CA).
  • cDNA synthesis kit and random priming labeling kits are obtained from Boehringer-Mannheim Biochemical (BMB, Indianapolis, IN). Oligonucleotide sequences encoding peptides can be either synthesized as described above. Alternatively, peptides can be synthesized directly by standard in vitro techniques (Applied Biosystems, Foster City CA).
  • FACS Fluorescent Cell Staining Assay.
  • Cells (10 6 /sample) were incubated in 10 ⁇ l primary antibody (10 ⁇ l/ml in PBS-BSA or HBSS (Hanks' Balanced Salt Solution, Gibco/BRL) supplemented with 1% BSA and 0.05% sodium azide) for 20 minutes at 4oC.
  • PBS-BSA or HBSS-BSA the primary antibody
  • the cells were incubated in 100 ⁇ l FITC-labeled F ab'2 fragments of goat anti-(mouse IgG) antibodies (Jackson, West Grove, PA) for 20 minutes at 4oC.
  • T cells were cultured with 3T6 fibroblasts transfected with the Fc ⁇ RIIa high responder allele and the B7 molecule (de Boer, M. et al., Eur. J. Immunol. (1992) 22 :3071-3075). Proliferation was measured by 3 H-thymidine incorporation. Briefly, 4 x 10 4 T cells were cultured with 10 4 irradiated (2500 rads) 3T6-Fc ⁇ RII/B7 cells in 96-well flat-bottom tissue culture plates in 200 ⁇ l/well complete IMDM with or without anti-CD3 Mab CLB-T3/4.1. During the last 16 hours of a 72 hour culture period, the cells were pulsed with 1 ⁇ Ci/well 3 H-thymidine. Proliferation of T cells is expressed as the mean cpm of triplicate wells.
  • Cytotoxic T Cell Assay Purified T cells were cultured with 3T6 fibroblasts transfected with the Fc ⁇ RIIa high responder allele and the B7 molecule. Briefly, 10 6 T cells were cultured with 0.2 x 10 6 irradiated (2500 rads) 3T6-Fc ⁇ RII/B7 cells in 24-well flat-bottom tissue culture plates in 1 ml/well complete IMDM in the presence of anti-CD3 Mab UCHT1 for 3-4 days. The cytotoxic activity of the lymphocytes was analyzed in an anti-CD3-redirected cytotoxicity assay as described below.
  • MLC Mixed Lymphocyte Culture
  • Proliferation of purified T cells was measured in mixed lymphocyte cultures (MLC) using the EBV-transformed B cell line ARC as stimulator cells.
  • MLC mixed lymphocyte cultures
  • 5 x 10 4 T cells were cultured with 5 x 10 4 irradiated (5000 rads) stimulator cells in 96-well round-bottom tissue culture plates (Corning) in 200 ⁇ l/well complete IMDM medium.
  • the cells were pulsed with 1 ⁇ Ci/well 3 H-thymidine.
  • Proliferation of T cells is expressed as the mean cpm of triplicate wells.
  • For secondary MLCs cells were stimulated as described above for primary MLC.
  • the T cell blasts for secondary MLC were generated in 5- to 7-day primary MLC, with subsequent culture in the absence of the stimulator cells for 2-4 days.
  • the cytotoxic activity of T cells generated in primary or secondary MLC was analyzed in an anti-CD3-redirected cytotoxicity assay using the mouse P815 cells as described below.
  • the EBV-transformed B cells used to induce the CTL activity served as target cells.
  • CTL activity was determined in a 4 hour target cell lysis assay using P815 murine mastocytoma cells or ARC EBV-transformed B cells as targets.
  • P815 target cells the CTLs were bridged non-specifically to the target cells using the anti-CD3 Mab OKT3 at 2 ⁇ g/ml.
  • the ARC cells were used as target cells, only the alloantigen-specific CTLs participate in the killing process.
  • 10 6 target cells were incubated with 200 ⁇ Ci of 51 Cr-sodium chromate (Amsersham International) for one hour and subsequently washed.
  • the CTL assays were performed in 96-well V-bottom microtiter plates using 5000 51 Cr-labelled target cells with different amounts of effector cells in a total volume of 200 ⁇ l/well.
  • Four wells were filled with 5 x 10 3 target cells in 200 ⁇ l medium alone, and four wells with 5 x 10 3 target cells in 100 ⁇ l medium and 100 ⁇ l saponin (for evaluation of spontaneous and maximal release, respectively).
  • three wells were filled with effector cells and target cells in the absence of anti-CD3 Mab (to determine the background experimental lysis).
  • Three other wells also contained the anti-CD3 Mab at 2 ⁇ g/ml in order to determine the total lysis in the presence of anti-CD3.
  • Results are expressed as percentage of anti-CD3-dependent specific release with the P815 target cells, or as a percentage of alloantigen-specific release with the ARC target cells.
  • B-Cell Proliferation Assay B cells (4 x 10 4 per well) were cultured in 200 ⁇ l IMDM supplemented with 10% fetal calf serum in flat bottom 96-well microtiter plates. B cells were stimulated by addition of immobilized anti-(IgM) antibodies (Immunobeads; 5 ⁇ g/ml; BioRad, Richmond, CA). Where indicated 100 U/ml recombinant IL-2 was added. Varying concentrations of mAbs were added at the onset of the microcultures and proliferation was assessed at day 3 by measurement of the incorporation of [ 3 H]-thymidine after 18 hour pulsing.
  • mouse 3T6 transfectant cells expressing the HR allellic form of human Fc ⁇ RII were used.
  • B cells (2 x 10 4 per well) were cultured in flat-bottom microwells in the presence of 1 x 10 4 transfectant cells (irradiated with 5000 Rad) in 200 ⁇ l IMDM supplemented with 10% fetal calf serum and 100 U/ml recombinant IL-4.
  • the 3T6 cells were allowed to adhere to the culture plastic for at least 5 hours.
  • Anti-CD40 mAbs were added at concentrations varying from 15 ng/ml to 2000 ng/ml and proliferation of B cells was assessed by measurement of thymidine incorporation at day 7, upon 18 hour pulsing with [ 3 H]-thymidine.
  • B-Cell Activation Assay with EL4B5 Cells B cells (1000 per well) were cultured together with irradiated (5000 Rad) EL4B5 cells (5 x 10 4 per well) in flat bottom microtiter plates in 200 ⁇ l IMDM supplemented with 10% heat-inactivated fetal calf serum, 5 ng/ml phorbol-12-myristate 13-acetate (Sigma) and 5% human T-cell supernatant. MAbs were added at varying concentrations at the onset of the cultures and thymidine incorporation was assessed at day 6 after 18 hour pulsing with [ 3 H]-thymidine.
  • T-cell supernatant For the preparation of T-cell supernatant, purified T cells were cultured at a density of 10 6 /ml for 36 hours in the presence of 1 ⁇ g/ml PHA and 10 ng/ml PMA. Wen et al., supra. T-cell supernatant was obtained by centrifugation of the cells and stored at -20oC. The effectiveness of T-cell supernatants in enhancing proliferation of human B cells in EL4B5-B cell cultures was tested and the most effective supernatants were pooled and used in the experiments.
  • the concentrations of human IgM and IgG were estimated by ELISA.
  • PBS-Tween PBS-0.05 % Tween-20
  • ARC cells (10 6 cells/sample) were incubated in 100 ⁇ l primary antibody (10 ⁇ g/ml in PBS-BSA or Hanks' balanced salt solution (HBSS) supplemented with 1% BSA and 0.05% sodium azide) for 20 min at 4°C. After 3 washes with PBS-BSA or HBSS-BSA, the cells were incubated in 100 ⁇ l FITC-labeled F(ab') 2 fragments of goat anti-(mouse IgG) antibodies (Jackson, West Grove, PA) for 20 min at 4°C.
  • primary antibody 10 ⁇ g/ml in PBS-BSA or Hanks' balanced salt solution (HBSS) supplemented with 1% BSA and 0.05% sodium azide
  • EL4B5 cells were harvested before and at different time points during culture in medium containing PMA (5ng/ml) and human T-cell supernatant (5%). Cells were incubated for 30 minutes with 10 ⁇ l supernatant of transfected cells containing hCD40-H ⁇ diluted in 100 ⁇ l Hank's Balanced Salt Solution supplemented with 0.05% sodium azide (4oC). This was followed by incubation with FITC-conjugated F(ab') 2 fragments of rabbit anti-(human IgM) (Central Laboratory of the Blood Transfusion Service, Amsterdam, The Netherlands). As a control, cells were incubated with the FITC-conjugate only. For analysis a FACScan-4 cytofluorometer (Becton and Dickinson) was used. Non-vital cells were excluded from analysis by the use of propidium iodide.
  • RNA was isolated from a population of EBV-transformed human spleen cells essentially as described by Chirgwin et al . (1979). In brief, the cells were washed twice with phosphate buffered saline (PBS) and lysed in 5 M guanidinium thiocyanate in the presence of 0.7 M 2-mercaptoethanol. The cell lysate was layered on a discontinuous CsCl gradient (Chirgwin, et al .) and centrifuged for 16 hours at 26,000 rpm in a Beckman SW28 rotor. The RNA was recovered by dissolving the pellet in DEPC-treated H 2 O. The RNA was precipitated with ethanol once, resuspended in DEPC treated H 2 O, and stored at -70°C.
  • PBS phosphate buffered saline
  • RNA (10 ⁇ g/reaction) was converted to cDNA using random hexamer priming in 50 ⁇ l reaction buffer containing 500 units LMV-RT (Bethesda Research Laboratories, Bethesda, MD), 5 ⁇ M random hexamers (Pharmacia, Piscataway, NJ), 1 mM DTT, dNTP mix (0.5 mM each), 10 mM Tris-HCL pH 8.3, 50 mM KCl, 2.5 mM MgCl 2 and 0.1 mg/ml BSA (bovine serum albumin). After incubation at 37°C for 1 hour, the samples were boiled for 3 min and stored at -70°C.
  • LMV-RT Bethesda Research Laboratories, Bethesda, MD
  • 5 ⁇ M random hexamers Pharmacia, Piscataway, NJ
  • 1 mM DTT 1 mM each
  • the DNA encoding CD40 was generated by PCR using primers which contained sequences having homology to known CD40 sequence, where the primers also encoded restriction sites useful for cloning ( Figure 2). These primers were based on the published cDNA coding sequences for CD40 (Stamenkovic et al. , 1989). All primers start with a C-G clamp at the 5' end followed by a restriction site for cloning (shown in bold, Figure 2). The underlined sequences in the backward primers, for the cloning of the soluble form of CD40, represents an epitope recognized by a monoclonal antibody used for affinity purification. The numbers in brackets represent the location of the primers relative to the published cDNA for CD40.
  • PCR amplification 1 ⁇ l of cDNA was mixed 1 ⁇ l (10 picomoles) of a forward primer, 1 ⁇ l (10 picomoles) of a backward primer, and 47 ⁇ l of PCR mix.
  • the PCR mix consisted of 1.25 units Taq polymerase (Perkin-Elmer/Cetus, Norwalk, CT), dNTP mix (0.2 mM each), 10 mM Tris-cHL pH 8.3, 50 mM KCl, 2.5 mM MgCl 2 and 0.1 mg/ml BSA.
  • PCR mixture was overlaid with 70 ⁇ l mineral oil and subjected to 25 cycles of amplification in a Perkin-Elmer/Cetus thermocycler (denaturation at 95°C for 30 sec, primer annealing at 55°C for 30 sec and extension at 72°C for 1.5 min). PCR products were obtained after 25 amplification cycles.
  • the amplification products were digested with BglII and KpnI ( Figure 1B) and isolated by size-fractionation. Before expression in baculovirus, the DNA sequence of each fragment was confirmed by sequencing analysis to prevent the introduction of PCR-induced mutations.
  • the baculovirus transfer vector pAcC8 was also digested with BgIII and KpnI ( Figure 1B).
  • the amplified fragments were ligated to the linear pAcC8 vector (ratio of insert to vector was 3:1).
  • the ligation products were transformed into bacterial strain DH5 ⁇ (Gibco/BRL, Gaithersburg MD) and recombinant pAcC8 vectors were selected on the basis of ampicillin resistance.
  • Recombinant plasmids were isolated from bacterial clones (Maniatis, et al.; Ausubel, et al.) and the presence of the insert of interest verified using polymerase chain reactions (see above). Large scale plasmid preparation was performed by standard procedures (Ausubel, et al .; Maniatis, et al .; Sambrook, et al .).
  • Sequences encoding human CD40 and human B7 were recombined into the Autographa californica baculovirus (AcNPV) using the transfer vectors pAcCD40 (encoding the full-length CD40 molecule) and pAcCD40-ED/Glu (encoding the extracellular domain of CD40).
  • the plasmids were cotransfected with wild-type baculoviral DNA (2-10 pfu) (AcNPV; Summers et al. ) into SF9 ( Spodoptera frugiperda ) cells at a density of 10 6 cells/ml (Summers et al. ). Recombinant baculovirus-infected Sf9 cells were identified and clonally purified (Summers et al .).
  • the cells were harvested after 48 hours of culture; for the production of secreted recombinant proteins, the cells were harvested after 72 hours of culture.
  • Sf9 insect cells infected with recombinant virus were cultured for 48 hours in 24-well plates. After removal of the tissue culture medium the plates were incubated for 45 min at room temperature (RT) with 0.25 ml of antibody in PBS with 1% BSA (PBS-BSA). After three washed with PBS-BSA, the plates were incubated for 35 min at RT with 250 ⁇ l of a 1/250 dilution of goat anti-(mouse total Ig) immunoglobulins conjugated to horseradish peroxidase (Zymed, South San Francisco, CA) in PBS-BSA. Unbound peroxidase activity was removed by washing five times with PBS-BSA.
  • Bound peroxidase activity was revealed by the addition of an assay mixture prepared by diluting 0.5 ml of 2 mg/ml 3,3',5,5'-tetramethylbenzidine in ethanol to 10 ml with 10 mM Na acetate, 10 mM EDTA buffer (pH 5.0) and adding 0.03% (v/v) H 2 O 2 . The reaction was stopped after 10 min by adding 100 ⁇ l of 1 M H 2 SO 4 .
  • Figure 3 presents the data for live Sf9 cells infected with pAcB7 and pAcCd40 which were cultured for 48 hours in 24-well plates.
  • the antibodies used in the ELISA were: S2C6, anti-(CD40) (open bars) and no primary antibody (hatched bars).
  • Cells (10 6 /sample) were incubated in 10 ⁇ l primary antibody (10 ⁇ g/ml in PBS-BSA or HBSS (Hanks' Balanced Salt Solution, Gibco/BRL) supplemented with 1% BSA and 0.05% sodium azide) for 20 min at 4°C. After 3 washes with PBS-BSA or HBSS-BSA, the cells were incubated in 100 ⁇ l FITC-labeled Fab '2 fragments of goat anti-(mouse IgG)antibodies (Jackson, West Grove, PA) for 20 min at 4°C.
  • primary antibody 10 ⁇ g/ml in PBS-BSA or HBSS (Hanks' Balanced Salt Solution, Gibco/BRL) supplemented with 1% BSA and 0.05% sodium azide
  • FIG. 5A The data for fluorescent cell staining of ARC EBV transformed B cells is presented in Figure 5.
  • Figure 5A the results for staining at 1:100 dilution of serum from a mouse immunized with B7 expressing Sf9 cells (solid line) or a 1:100 dilution of normal mouse serum (dotted line) are shown.
  • ARC EBV-transformed B cells were stained with anti-(B7) and anti-(CD40) monoclonal antibodies in the presence and absence of soluble B7 and soluble CD40.
  • the antibodies and the soluble B7, soluble CD40 or controls were preincubated at RT for 20 min before addition to the ARC cells.
  • Figure 6A shows the results of staining with B7-24 (dotted line) or secondary antibody only (solid line).
  • Figure 6B shows the results of staining with B7-24 alone (dotted line) or B7-24 preincubated with soluble B7 (solid line).
  • Figure 6C shows the results of staining with B7-24 alone (dotted line) or B7-24 preincubated with soluble CD40.
  • Figure 6D shows the results of staining with CD40-3A8 (dotted line) or second antibody alone (solid line).
  • Figure 6E shows the results of staining with CD407A8 alone (dotted line) or CD403A8 preincubated with soluble B7 (solid line).
  • Figure 6F shows the results of staining with CD403A8 alone (dotted line) or preincubated with soluble CD40 (solid line).
  • mice Female BALB/c mice were injected intraperitoneally at day 0 and day 14 with 5x10 6 Sf9 cells infected with AcCD40 virus, AcB7 virus or AcCd3 virus (control virus). At day 21, 100 ⁇ l of serum was obtained to test for the presence of specific antibodies. After a rest period of at least two weeks, the mice received a final injection with 5 ⁇ 10 6 cells infected with AcCD40 or AcB7 virus. Three days after this last injection, the spleen cells were used for cell fusion.
  • Splenocytes from immunized BALB/c mice were fused with SP2/0 murine myeloma cells at a ratio of 10:1 using 50% polyethylene glycol as previously described by de Boer et al. (1988).
  • the fused cells were resuspended in complete IMDM medium supplemented with hypoxanthine (0.1 mM), aminopterin (0.01 mM), thymidine (0.016 mM) and 0.5 ng/ml hIL-6 (Genzyme, Cambridge, MA).
  • the fused cells were then distributed between the wells of 96-well tissue culture plates, so that each well contained 1 growing hybrid on average.
  • Tonsillar B lymphocytes were isolated from tonsils obtained from children undergoing tonsillectomy as described by deGroot et al . (1990). Briefly, the tissue was dispersed with scalpel blades, phagocytic cells and NK cells were depleted by treatment with 5 mM L-leucine methyl ester and T cells were removed by one cycle of rosetting with sheep erythrocytes treated with 2-aminoethyl isothiouronium bromide.
  • the anti-(CD40) and anti-(B7) monoclonal antibodies were tested for their ability to bind to tonsillar B cells using the fluorescent cell staining assay described above in Example 4.
  • propidium iodine was used to exclude dead cells.
  • Table 2 shows the results of the above analysis for the binding of anti-(CD40) monoclonal antibodies to highly enriched tonsillar B cells.
  • Table 2 Binding of Anti-(CD40) Monoclonal Antibodies to Highly Enriched Tonsillar B Cells Antibody Specificity % of Positive Cells a OKT3 CD3 2.1 LeuM3 LeuM3 2.5 B1 CD20 88.0 G28.5 CD40 92.1 CD40-5H7 CD40 93.7 CD40-5D12 CD40 95.0 CD40-3C6 CD40 88.9 CD40-3A8 CD40 93.3 a The percentage of positive tonsillar cells was measured by fluorescent cell staining as described in Example 4.
  • Human tonsillar B cells (4 x 10 4 per well) were cultured in 200 ⁇ l in microwells in the presence of anti-IgM coupled to Sepharose beads (5 ⁇ /ml) ( Figure 7A) or in the presence of anti-IgM plus rIL-2 (100 U/ml) ( Figure 7B).
  • Varying concentrations of the anti-CD40 mAbs S2C6, 5D12, 3C6 or 3A8 were added and [ 3 H]thymidine incorporation was measured at day 3 after 18 h pulsing.
  • Data presented in Figure 7A are means derived from experiments with B-cell preparations from three different donors with duplicate incubations.
  • Data of Figure 7B are means of duplicate incubations from one experiment out of two with comparable results.
  • anti-CD40 mAb S2C6 costimulated human B-cell proliferation in a concentration dependent fashion.
  • the mAbs tested in Example 8 were tested for their ability to induce proliferation of human B cells in the Banchereau-like Assay described above, i.e., by presenting the anti-CD40 mAb on adherent cells expressing Fc ⁇ RII.
  • As antibody presenting cells mouse 3T6 transfectant cells expressing the HR allellic form of human Fc ⁇ RII were used. It was observed that anti-CD40 mAb S2C6 together with IL-4 induced substantial proliferation of tonsillar human B cells in this system, as assessed by measurement of [ 3 H]thymidine incorporation.
  • Anti-CD40 mAbs 5D12, 3C6 or 3A8 did not induce proliferation of human B cells in this culture system (data not shown).
  • the anti-CD40 mAbs were also tested for their ability to inhibit the costimulation of human B-cell proliferation by anti-CD40 mAb S2C6 using the B-cell Proliferation Assay described above.
  • Human tonsillar B cells (4 x 10 4 per well) were cultured in 200 ⁇ l in microwells in the presence of anti-IgM coupled to Sepharose beads (5 ⁇ g/ml) and anti-CD40 mAb S2C6 (1.25 ⁇ g/ml). Varying concentrations of anti-CD40 mAbs 5D12, 3C6 or 3A8 were added and [ 3 H]thymidine incorporation was assessed after 3 days.
  • Figure 9 shows that addition of anti-CD40 mAbs 5D12, 3C6 or 3A8 resulted in a concentration-dependent inhibition of human B-cell proliferation.
  • Data are means ⁇ S.D. derived from experiments with B cells from four different donors with duplicate incubations.
  • [ 3 H]-thymidine incorporation values found for incubations without mAb were (means ⁇ S.D.) 10460 ⁇ 1843 cpm, 6982 ⁇ 1729 cpm, 4362 ⁇ 1020 cpm and 1543 ⁇ 3190 in the four different experiments, respectively.
  • [ 3 H]-thymidine incorporation in B cells alone amounted to 40 ⁇ 5 cpm and in irradiated EL4B5 cells alone 31 ⁇ 15 cpm.
  • anti-CD20 mAb B1 or anti-B7 mAb B7-24 were generated by a procedure similar to that used for generating the anti-CD40 mAb used in Figure 9 in concentrations similar to those used in the experiments with the anti-CD40 mAb, had any effect on EL4B5-induced human B-cell proliferation (data not shown). Therefore, it may be concluded that the inhibitory effect of anti-CD40 mAb on EL4B5-induced B-cell proliferation is not due to masking of the B-cell surface.
  • a fusion protein consisting of the extracellular domain of CD40 and human IgM constant domains CH 2 , CH 3 and CH 4 (hCD40.H ⁇ ) was used for flow fluorocytometric analysis. Lane et al., supra. Non-activated EL4B5 cells did not bind the fusion protein. However, upon culturing EL4B5 cells together with PMA (5 ng/ml) and 5% human T-cell supernatant, which are the conditions needed for activation of human B cells, a low binding of hCD40.H ⁇ was found (data not shown). This small shift in fluorescence was found consistently in three independent experiments.
  • the minimal activation period needed for induction of the CD40 binding was 24 hours.
  • the fusion protein was titrated into cocultures of EL4B5 cells with human B cells using the B-cell Activation Assay described above.
  • Figure 10 shows that the fusion protein did indeed inhibit [ 3 H]-thymidine incorporation in a concentration-dependent manner and, like the anti-CD40 mAb used in the experiments shown in Figure 9, was able to inhibit B-cell proliferation induced by the EL4B5 cells completely.
  • the antibodies were also tested for their capacity to inhibit immunoglobulin production by B cells, stimulated in a contact-dependent manner with activated T cells using the T-cell helper assay described above.
  • Human tonsillar B cells (10 4 /well) were cultured together with irradiated purified T cells (3000 rad, 10 5 /well) in 96-well plates, coated with anti-CD3 mAb and with or without different mAbs to costimulate the T cells. After 8 days of culture the supernatants were harvested for the determination of immunoglobulin production by the B cells. Immunoglobulin production by the B cells was assessed by the ELISA assay described above.
  • Anti-CD40 mAb 5D12 was added in varying concentrations from the onset of the cultures.
  • FIG. 4A shows that when T cells were stimulated with immobilized anti-CD3 mAb and costimulated with soluble anti-CD2 and anti-CD28 mAbs, addition of anti-CD40 mAb 5D12 resulted in a concentration dependent inhibition of IgG production by human B cells. IgM production by the B cells was inhibited to the same extent. Similar results were obtained with the anti-CD40 mAbs 3C6 and 3A8 and with the hCD40.H ⁇ fusion protein.
  • the anti-CD40 mAbs of this invention exhibited very potent inhibition. At concentrations as low as approximately 30 ng/ml, each of the three anti-CD40 mAbs gave 50% of maximal inhibition. In contrast, the isotype-matched IgG2b mouse myeloma protein MOPC-141 had no effect on the immunoglobulin production.
  • FIG. 4B shows that under all the T-cell stimulation conditions (anti-CD3 alone; anti-CD3 + anti-CD2; anti-CD3 + anti-CD28; and anti-CD3 + anti-CD2 + anti-CD28), addition of the anti-CD40 mAb 5D12 results in strong inhibition of immunoglobulin production by the human B cells.
  • the inhibition is comparable to the amount of inhibition with the hCD40.H ⁇ fusion protein, known to completely block the CD40-CD40 ligand interaction.
  • the percentage of inhibition varied from 40 to 70% depending on the T-cell activation conditions.
  • the isotype-matched IgG2b mouse myeloma protein MOPC-141, or human IgM had no effect on immunoglobulin production by the human B cells.
  • hybridomas used in the above examples were deposited in and accepted by the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, USA, under the terms of the Budapest Treaty. This deposition does not indicate that these hybridomas are necessary to practice the invention described above or claimed below.
  • ATCC American Type Culture Collection

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (12)

  1. Anticorps monoclonal ou fragment de celui-ci capable de se lier à un antigène CD40 humain situé sur la surface d'une cellule B humaine, dans lequel la liaison de l'anticorps ou du fragment de celui-ci à l'antigène CD40 empêche la croissance ou la différenciation de la cellule B.
  2. Anticorps monoclonal selon la revendication 1, choisi parmi les anticorps monoclonaux 5D12, produit par l'hybridome ATCC HB 11339 et 3C6, produit par l'hybridome ATCC HB 11340.
  3. Anticorps monoclonal ou fragment de celui-ci selon la revendication 1 ou la revendication 2, qui est humanisé.
  4. Anticorps monoclonal ou fragment de celui-ci selon la revendication 3, dans lequel ledit fragment est un fragment Fab', F(ab')2 ou Fv.
  5. Hybridome capable de produire un anticorps monoclonal ayant une spécificité pour l'antigène CD40 d'une cellule B humaine, dans lequel la liaison dudit anticorps monoclonal à un antigène CD40 humain exprimé sur la surface d'une cellule B humaine inhibe la croissance ou la différenciation de la cellule B.
  6. Hybridome selon la revendication 5, qui produit l'anticorps monoclonal 5D12 ayant le numéro de dépôt ATCC HB 11339.
  7. Hybridome selon la revendication 5, qui produit l'anticorps monoclonal 3C6 ayant le numéro de dépôt ATCC HB 11340.
  8. Utilisation d'un anticorps monoclonal anti-CD40 ou d'un fragment de celui-ci capable de se lier à un antigène CD40 humain situé sur la surface d'une cellule B humaine dans la fabrication d'un médicament pour prévenir ou traiter une maladie médiée par les anticorps chez un patient, dans laquelle la liaison de l'anticorps ou du fragment de celui-ci à l'antigène CD40 empêche la croissance ou la différenciation de la cellule B.
  9. Utilisation selon la revendication 8, dans laquelle la maladie médiée par les anticorps est choisie dans le groupe constitué par une maladie médiée par les IgE comme le lupus érythémateux disséminé (LED), la cirrhose biliaire primaire (CBP) et le purpura thrombopénique idiopathique (PTI).
  10. Utilisation d'un anticorps monoclonal anti-CD40 ou fragment de celui-ci capable de se lier à un antigène CD40 humain situé sur la surface d'une cellule B humaine dans la fabrication d'un médicament pour inhiber la prolifération des cellules B humaines, la prolifération desdites cellules B étant augmentée par l'interaction d'un ligand CD40 avec un antigène CD40 exprimé sur la surface desdites cellules B, dans laquelle la liaison dudit anticorps monoclonal anti-CD40 audit antigène CD40 empêche la croissance ou la différenciation de ladite cellule B.
  11. Composition pharmaceutique comprenant :
    (a) un anticorps monoclonal ou un fragment de celui-ci qui est capable de se lier spécifiquement à un antigène CD40 humain exprimé sur la surface d'une cellule B humaine, dans laquelle la liaison de l'anticorps ou du fragment à l'antigène CD40 empêche la croissance ou la différenciation de la cellule B ; et
    (b) un excipient pharmaceutique.
  12. Composition pharmaceutique selon la revendication 11, dans laquelle l'anticorps monoclonal est tel que défini dans la revendication 2, dans la revendication 3 ou dans la revendication 4.
EP99104709A 1992-07-09 1993-07-08 Anticorps monoclonaux antagonistes contre la molécule humaine CD40 Revoked EP0945465B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06076491.7A EP1834671A3 (fr) 1992-07-09 1993-07-08 Procédé pour l'induction des anticorps contre des molecules exprimées sur la surface des cellules

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US07/910,222 US5397703A (en) 1992-07-09 1992-07-09 Method for generation of antibodies to cell surface molecules
US910222 1992-07-09
US08/015,147 US5869050A (en) 1992-07-09 1993-02-09 Methods of blocking T-cell activation using anti-B7 monoclonal antibodies
US15147 1993-02-09
US70158 1993-05-28
US08/070,158 US5677165A (en) 1992-07-09 1993-05-28 Anti-CD40 monoclonal antibodies capable of blocking B-cell activation
EP93917032A EP0651797B1 (fr) 1992-07-09 1993-07-08 Procede permettant de produire des anticorps contre des molecules de surface des cellules

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP93917032A Division EP0651797B1 (fr) 1992-07-09 1993-07-08 Procede permettant de produire des anticorps contre des molecules de surface des cellules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06076491.7A Division EP1834671A3 (fr) 1992-07-09 1993-07-08 Procédé pour l'induction des anticorps contre des molecules exprimées sur la surface des cellules

Publications (2)

Publication Number Publication Date
EP0945465A1 EP0945465A1 (fr) 1999-09-29
EP0945465B1 true EP0945465B1 (fr) 2006-09-13

Family

ID=27360277

Family Applications (3)

Application Number Title Priority Date Filing Date
EP93917032A Expired - Lifetime EP0651797B1 (fr) 1992-07-09 1993-07-08 Procede permettant de produire des anticorps contre des molecules de surface des cellules
EP99104709A Revoked EP0945465B1 (fr) 1992-07-09 1993-07-08 Anticorps monoclonaux antagonistes contre la molécule humaine CD40
EP06076491.7A Withdrawn EP1834671A3 (fr) 1992-07-09 1993-07-08 Procédé pour l'induction des anticorps contre des molecules exprimées sur la surface des cellules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP93917032A Expired - Lifetime EP0651797B1 (fr) 1992-07-09 1993-07-08 Procede permettant de produire des anticorps contre des molecules de surface des cellules

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP06076491.7A Withdrawn EP1834671A3 (fr) 1992-07-09 1993-07-08 Procédé pour l'induction des anticorps contre des molecules exprimées sur la surface des cellules

Country Status (5)

Country Link
EP (3) EP0651797B1 (fr)
AT (2) ATE258595T1 (fr)
DE (2) DE69334064T2 (fr)
DK (1) DK0945465T3 (fr)
ES (1) ES2273452T3 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361345B2 (en) 1992-07-09 2008-04-22 Novartis Vaccines And Diagnostics, Inc. Anti-CD40 antibodies capable of blocking B-cell activation

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034649A2 (fr) * 1999-11-09 2001-05-17 Chiron Corporation Compositions et methodes de traitement de maladies auto-immunes et des rejets de greffon
CN1450912A (zh) * 2000-04-19 2003-10-22 泰诺士公司 用于治疗牛皮癣和其它炎性皮肤病的cd40拮抗剂
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
AU2001259215A1 (en) * 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
WO2002028905A2 (fr) * 2000-10-02 2002-04-11 Chiron Corporation Anticorps humains anti-cd40
EP2009027B1 (fr) 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-CD40
DE10132308A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Kombinationspräparat zur Therapie von immunologischen Erkrankungen
WO2003028809A1 (fr) * 2001-10-02 2003-04-10 Chiron Corporation Procede pour traiter la malignite de lymphocytes b
WO2003029296A1 (fr) * 2001-10-02 2003-04-10 Chiron Corporation Anticorps humains diriges contre le cd40
JP2008509080A (ja) * 2004-04-27 2008-03-27 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アンタゴニスト抗ｃｄ４０モノクローナル抗体およびその使用方法
EP1854810A1 (fr) 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
WO2017059243A2 (fr) * 2015-09-30 2017-04-06 Janssen Biotech, Inc. Anticorps agonistes se liant de manière spécifique au cd40 humain et procédés d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000092A1 (fr) * 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand pour recepteur a cd28 sur des lymphocytes b et procedes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLARK . AND SHU G.: "Association between IL-6 and CD40 signalling", JOURNAL OF IMMUNOLOGY, vol. 145, no. 5, 1 September 1990 (1990-09-01), pages 1400 - 1406 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361345B2 (en) 1992-07-09 2008-04-22 Novartis Vaccines And Diagnostics, Inc. Anti-CD40 antibodies capable of blocking B-cell activation
US7790166B2 (en) 1992-07-09 2010-09-07 Novartis Vaccines And Diagnostics, Inc. Anti-CD40 antibodies capable of blocking B-cell activation

Also Published As

Publication number Publication date
ATE258595T1 (de) 2004-02-15
EP0651797A1 (fr) 1995-05-10
ES2273452T3 (es) 2007-05-01
DE69334064D1 (de) 2006-10-26
ATE339451T1 (de) 2006-10-15
EP0651797B1 (fr) 2004-01-28
DE69333403D1 (de) 2004-03-04
DK0945465T3 (da) 2007-01-15
DE69334064T2 (de) 2007-05-24
EP0945465A1 (fr) 1999-09-29
EP1834671A3 (fr) 2013-05-22
DE69333403T2 (de) 2004-11-11
EP1834671A2 (fr) 2007-09-19

Similar Documents

Publication Publication Date Title
CA2125472C (fr) Methode de generation d'anticorps contre des molecules de la surface cellulaire
AU694760B2 (en) B7-1-specific ligands, and their use for the induction of T cell anergy
EP0896585B1 (fr) Anticorps monoclonaux humanises de type anti-cd40 et fragments capables de bloquer l'activation des lymphocytes b
EP1326896B1 (fr) Anticorps humains diriges contre cd40
WO2003029296A1 (fr) Anticorps humains diriges contre le cd40
EP0945465B1 (fr) Anticorps monoclonaux antagonistes contre la molécule humaine CD40

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990310

AC Divisional application: reference to earlier application

Ref document number: 651797

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030717

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

AC Divisional application: reference to earlier application

Ref document number: 0651797

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20060913

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69334064

Country of ref document: DE

Date of ref document: 20061026

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20060404336

Country of ref document: GR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20061212

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2273452

Country of ref document: ES

Kind code of ref document: T3

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: BRISTOL-MYERS SQUIBB COMPANY

Effective date: 20070608

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: THIRKETTLE, LINDA ELKE

Effective date: 20070613

Opponent name: BRISTOL-MYERS SQUIBB COMPANY

Effective date: 20070608

NLR1 Nl: opposition has been filed with the epo

Opponent name: THIRKETTLE, LINDA ELKE

Opponent name: BRISTOL-MYERS SQUIBB COMPANY

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20090629

Year of fee payment: 17

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20090629

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20090717

Year of fee payment: 17

Ref country code: FR

Payment date: 20090710

Year of fee payment: 17

Ref country code: ES

Payment date: 20090812

Year of fee payment: 17

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20090708

Year of fee payment: 17

Ref country code: LU

Payment date: 20090804

Year of fee payment: 17

Ref country code: GR

Payment date: 20090619

Year of fee payment: 17

Ref country code: GB

Payment date: 20090708

Year of fee payment: 17

Ref country code: DE

Payment date: 20090702

Year of fee payment: 17

Ref country code: CH

Payment date: 20090721

Year of fee payment: 17

Ref country code: AT

Payment date: 20090715

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20090805

Year of fee payment: 17

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

27W Patent revoked

Effective date: 20091208

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Effective date: 20091208

REG Reference to a national code

Ref country code: PT

Ref legal event code: MP4A

Effective date: 20100505

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 20060913

Ref country code: CH

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 20060913

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20100707

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20100719

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20100712

Year of fee payment: 18